Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 13/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009093 | 0.85 | GAA (0.38) | PROKR1GAANPC1HSD17B10 | |
| SCHEMBL30009910 | 0.85 | JAK1 (0.40) | PROKR1GAANPC1HSD17B10 | |
| SCHEMBL30009231 | 0.84 | TAS1R3 (0.43) | PROKR1TAS1R3TAS1R1TAS1R2GAA | |
| SCHEMBL30008788 | 0.82 | PROKR1 (0.44) | PROKR1 | |
| SCHEMBL30009418 | 0.81 | JAK1 (0.45) | PROKR1HSD17B10 | |
| SCHEMBL30009357 | 0.78 | TSHR (0.38) | — | |
| SCHEMBL937205 | 0.75 | PROKR1 (0.63) | PROKR1GFERTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL30009325 | 0.73 | HPGD (0.66) | GFERGAANPC1HSD17B10 | |
| SCHEMBL14211247 | 0.72 | PROKR1 (0.53) | PROKR1GFERTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL939096 | 0.72 | PROKR1 (0.63) | PROKR1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | PROKR1 921/4885GFER 4411/4885TAS1R3 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.